Blogerroom logoBlogerroom
Medical
Medical

FDA Sets May 2027 Date for Huntington's Gene Therapy

AS
Dr. Anand SharmaNovember 4, 20265 min read
Follow:FacebookยทPinterest
๐ŸŒ Language

FDA Sets May 2027 Date for Huntington's Gene Therapy

The FDA gave uniQure's AMT-130 priority review for Huntington's, but the case rests on 12 patients and an external control, and a panel is planned.

A gene therapy for Huntington's disease now has an FDA decision date: May 1, 2027. On Nov. 2, uniQure N.V., the company behind the treatment, which lists offices in Amsterdam and Lexington, Massachusetts, announced that the agency had accepted its application for ifezuntirgene inilparvovec, known as AMT-130, and granted it Priority Review under the Accelerated Approval pathway.

It is real progress. It is also a long way short of an approval, and the evidence behind the filing is thinner than the headline suggests.

What the FDA actually agreed to

According to uniQure's announcement, the FDA's acceptance letter set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. Priority Review shortens the agency's action goal to six months, compared with ten for a standard review, as one trade report noted. It affects speed, not the standard of evidence.

The letter also said the FDA is tentatively planning to discuss the application at an advisory committee meeting, with no date set. That is worth reading closely. An advisory committee means outside experts will examine the data in public and vote, and the vote is not binding on the FDA.

uniQure says that if approved this would be the world's first disease-modifying treatment for Huntington's disease. Huntington's affects an estimated 75,000 people across the U.S., EU and UK, according to uniQure, and there are currently no approved therapies to delay its onset or slow its progression.

Article image 1

The evidence: 12 patients and an external comparison

The application rests on 36-month data from the high-dose cohorts of two Phase I/II trials, according to Neurology Advisor, covering 12 patients. Their outcomes were compared with propensity score-matched controls drawn from Enroll-HD, a natural history database, rather than with a placebo group in the same trial. uniQure announced that analysis on Sept. 24, 2025, and reported 75% slower decline on the composite Unified Huntington's Disease Rating Scale (cUHDRS) than the external control, with a p-value of 0.003.

An external control is a legitimate tool in a rare disease where recruiting a large placebo group is hard. It is also vulnerable to bias, because the patients in the database were never randomised against the treated group.

The regulatory path has not been smooth. uniQure said in November 2025 that the FDA no longer agreed an external control could be the main evidence, according to a biotech newsletter, and in September 2026 the company said the agency had communicated that the 36-month data from 12 patients could serve as the primary basis of the filing. Both of those accounts come from the company.

The softer 48-month result

Newer data complicate the picture. In a later analysis, the cUHDRS showed 44% slowing against external controls, a result that was not statistically significant (p=0.144), according to a news report on the company's disclosure. uniQure attributed the weaker comparison to missing data and survivor bias in the external control, and said those later results were not part of the original application.

One analyst read the update more favourably. Lachlan Hanbury-Brown, quoted by Benzinga, pointed to Total Functional Capacity (TFC), which he called the more important regulatory endpoint, where separation from the external control grew from three to four years after treatment. The same dataset, in other words, produces a weaker number on one measure and a stronger one on another.

My read: that is exactly the kind of argument an advisory committee exists to settle. Neither number should be treated as final until someone outside the company has tested it in public.

Article image 2

What patients are being asked to accept

AMT-130 is a one-time treatment delivered by MRI-guided neurosurgery directly into the striatum, a deep brain region, according to uniQure. It uses a microRNA designed to silence the huntingtin gene and a potentially toxic fragment of its protein. The Phase I/II programme has dosed 51 patients, including 13 in a European open-label study.

That is a serious procedure with a long-term question mark attached, since the effect on the lifelong course of the disease is still unknown. The confirmatory trial is meant to supply the missing evidence: a randomised study of about 200 patients, split 2:1 between AMT-130 and standard of care, with TFC at 36 months as the primary endpoint. uniQure plans to begin screening in the U.S. by the end of 2026.

What to watch

Three markers decide how this goes. The first is the advisory committee date, which will show how much scrutiny the FDA expects. The second is whether the confirmatory trial is enrolling by the time of any decision, because uniQure says it expects the study to be well underway by then. The third is whether the panel treats the 48-month result as noise from a flawed external control or as a warning.

For families affected by Huntington's, the story is a milestone and a caution at once. A decision date means the question will be answered within months. It does not mean the answer is yes.

ShareWhatsAppTwitterLinkedIn
AS

Written by

Dr. Anand Sharma

Doctor and science communicator.

Enjoyed this? Follow us:FacebookPinterest
โ† Back to Medical